Demyelinating Diseases (Demyelinating Disease)

04/01/2006 - "Immunocytochemical studies of cryotome sections to analyze developmental parameters of the oligodendroglial cell population at the time of termination of cuprizone and at different times thereafter showed that in the untreated animals, there was a marked increase in the number of NG2-BrdU-positive precursor cells together with a marked decrease in MBP expression at the peak of cuprizone-induced demyelination. "
11/01/2007 - "After chronic demyelination and removal of cuprizone from the diet, remyelination and oligodendrocyte density improved significantly in hPDGF-A tg mice compared with wild-type mice. "
01/01/2015 - "The current study evaluated the protective effects of Areca catechu nut extract (ANE) on a cuprizone-induced demyelination mouse model. "
01/01/2015 - "The Protective Effects of Areca catechu Extract on Cognition and Social Interaction Deficits in a Cuprizone-Induced Demyelination Model."
09/01/2015 - "A model of demyelination induced by cuprizone (CPZ) was used to observe the function of TH in remyelination during the remission period of MS. Through weighing and behavioral tests, we found that TH improved the physical symptoms of mice impaired by CPZ. "

10/01/2003 - "Here, we briefly summarize some of the most recently published data on both the deleterious and the protective effects of antibodies in autoimmune demyelinating disorders of the central nervous system."
07/01/2000 - "Anti-VLA-4 treatment dramatically reduced the cellular infiltrates and demyelination within the CNS but did not affect the clearance of virus while antibodies to CD44, ICAM and MAC-1 antibody treatment had no effect. "
04/01/2014 - "Although these antibodies are clinically relevant when associated with the specific neurological syndromes that have been described, further studies are required to evaluate their roles and clinical relevance in demyelinating diseases."
08/01/2013 - "These studies indicate that MOG antibodies could be associated with a broad spectrum of acquired human CNS demyelinating diseases. "
01/01/2001 - "The study lends support to the possibility that antisulphatide antibodies could contribute to tissue damage and this might facilitate the invasive growth in primary brain tumours by demyelination. "

10/01/1992 - "A better understanding of the multiple effector mechanisms operating in inflammatory demyelination may help to devise more efficacious antigen non-specific therapy."
02/01/1985 - "Because all animals had delayed onset of disease, this study demonstrates that the ability to develop relapsing inflammatory demyelination is transferable with lymphocytes and does not require the presence of antigen."
11/01/1990 - "Although infectious virus, as measured by viral plaque assay, was cleared inefficiently from the central nervous systems of resistant F1 hybrid progeny mice, we found a direct correlation between local viral antigen production and demyelination. "
10/25/2013 - "Elevated expression of PPARγ has been observed in the spinal cord of EAE mice and in an in vitro model of antigen-induced demyelination; however, no reports have yet been available on the PPARγ status in the central nervous system of human individuals with MS. Aiming to identify a possible alteration, the present study assessed the levels of PPARγ protein in the cerebrospinal fluid (CSF) of MS patients via ELISA technique. "
05/01/2007 - "Our study highlights the role of microglia as a heterogeneous population of cells in primary demyelination, with the capacity to present antigen, proliferate, and migrate into demyelinated areas."

01/01/2002 - "TNFalpha: kill or cure for demyelinating disease?"
01/01/2012 - "The serum tumor necrosis factor-α (TNFα) was elevated and nerve conduction studies revealed demyelination both in the distal and intermediate segments. "
01/01/2005 - "In view of the cross-talk in TNF family signaling, the aim of this study is to understand the role of Ltalpha in demyelination and remyelination in hopes of improving therapeutic strategies for MS. Using the same model, we show that mice lacking Ltalpha exhibit a delay in demyelination that is greater than that exhibited by TNFalpha null mice. "
10/29/2003 - "We used Affymetrix microarrays in this study to identify (1) changes in gene expression that accompany demyelination versus remyelination and (2) changes in gene expression during the successful remyelination of wild-type mice versus the unsuccessful attempts in mice lacking TNFalpha. "
02/15/2000 - "The aim of this study was to define the significance of TNFalpha with respect to the hallmark of MS, that is demyelination. "

01/01/2010 - "Regional demyelination and the use of corticosteroids have been implicated, yet their mechanisms of action have not been elucidated. "
09/01/2009 - "The permeability of the blood-brain barrier is increased in experimental osmotic demyelination, and some have suggested that corticosteroids protect against this disorder by keeping the permeability of the blood-brain barrier low. "
12/01/2008 - "A possibility of demyelination was considered and he was treated with corticosteroids. "
03/01/2006 - "Corticosteroids delay remyelination of experimental demyelination in the rodent central nervous system."
05/24/2005 - "All patients had a monophasic disease, progressing over 4 to 8 weeks and characterized by predominantly motor features, areflexia, minimal or no cranial nerve abnormalities, no autonomic or respiratory involvement, elevated CSF protein, electrophysiologic evidence of demyelination, and good response to corticosteroids. "

12/01/1997 - "Our findings suggest that complement depletion by CVF is more effective than complement blockade by sCR1 in reducing the severity of inflammatory peripheral nerve demyelination."
11/15/2000 - "These results suggest that complement might be a target for the therapeutic treatment of inflammatory demyelinating diseases of the CNS."
06/01/2014 - "Future quantitative proteomic studies of the low-abundance myelin protein complement, likely representing key regulatory components, may in future provide molecular description of the dysmyelinating/demyelinating diseases."
07/01/2013 - "Previous studies from our laboratory using complement-mutant mice demonstrated that the alternative pathway is the dominant activation pathway responsible for complement-mediated pathology in demyelinating disease. "
09/01/2005 - "Recent studies revealed heterogeneity in the mechanisms leading to the formation of lesions, which include typical autoimmune patterns of demyelination involving T cells and macrophages, as well as antibody/complement as characteristic effector mechanisms. "

07/01/2012 - "Thymic gene transfer of myelin oligodendrocyte glycoprotein ameliorates the onset but not the progression of autoimmune demyelination."
12/01/2006 - "In this study, we analyzed a large spectrum of different rat strains actively immunized with myelin oligodendrocyte glycoprotein (MOG), a model strongly mimicking MS for cortical demyelination. "
10/01/2004 - "Clinicopathological study of a myelin oligodendrocyte glycoprotein-induced demyelinating disease in LEW.1AV1 rats."
12/01/2015 - "To evaluate the clinical relevance of myelin oligodendrocyte glycoprotein antibody (MOG-Ab) in a cohort of adults with inflammatory demyelinating disease (IDD) of the CNS. "
01/01/2015 - "EAE variants generated with the myelin component myelin oligodendrocyte glycoprotein (MOG) have emerged as the preferred ones, because in this particular variant disease is associated with both T- and B-cell effector mechanisms, together with demyelination. "

11/19/1999 - "The results suggest that one possible action of immunoglobulins in demyelinating diseases is an improved clearance of lesional debris with the removal of myelin-associated inhibitory molecules."
01/01/2014 - "To study cerebrospinal fluid and protein indices characterizing the permeability of the hematoencephalitic barrier and intrathecal immunoglobulin synthesis in children with different course and outcome of demyelinating diseases of the central nervous system. "
04/01/2000 - "Immunohistologic studies demonstrated increased cellular infiltrates, immunoglobulin precipitation, and demyelination in the Bcl-x(L) transgenic central nervous system (CNS) compared with controls. "
02/01/1981 - "Cell-type-specific markers and indirect immunofluorescence were used to study immunoglobulin binding to glial cells in dissociated cell cultures of human foetal optic nerve, spinal cord and dorsal root ganglion in sera from patients with demyelinating diseases, other neurological diseases and normal controls. "
01/01/2015 - "Response to IV immunoglobulin in a case of osmotic demyelination syndrome."

12/01/1972 - "Propagation continued past a single demyelinated internode until myelin thickness was uniformly reduced to less than 2.7% of normal myelin thickness.3. Paranodal demyelination was more effective in slowing impulse conduction than was uniform demyelination of an entire internode with an equivalent rise in overall internodal capacitance and conductance.4. The effects on conduction of demyelination of two adjacent internodes or of two internodes separated by a normal internode were more than the sum of the effects of demyelination of each internode individually.5. Propagation across a severely demyelinated internode was blocked with an increase in internal sodium concentration which had a trivial effect on conduction in a normal fibre.6. Propagation across a severely demyelinated internode was blocked with increased temperature at a temperature at which propagation proceeds normally across normal internodes.7. The similarity between the findings of the computer simulations and the experimental findings in demyelinated fibres is discussed."
12/01/2015 - "Current guidelines recommend serum sodium concentration correction targets of no more than 8 mEq/L per day in patients at high risk of osmotic demyelination syndrome. "
10/01/2015 - "We investigated the association between sodium correction and demographic and outcome variables, including occurrence of osmotic demyelination syndrome (ODS). "
04/01/2015 - "However, an overly rapid correction of serum sodium levels can lead to osmotic demyelination syndrome (ODS), a dreadful neurological picture. "
12/01/2014 - "This case report demonstrates that if serum sodium is re lowered early in the course of Osmotic demyelination syndrome (ODS), many of its devastating consequences may be avoided. "

01/01/1992 - "The efficacy of lysophosphatidyl choline (LPC) type I and type IV in producing demyelination was assessed in rat tibial and sural nerve. "
01/01/1980 - "In this study, the mode of formation of incisures and their development were examined by light and electron microscopy in remyelinating fibres (16-200 d) of the sural nerve of rats following lysophosphatidyl choline (LPC)-induced segmental demyelination. "
01/01/2005 - "Relaxation time measurements were carried out during the preacute stage of lesion progression in an animal model of demyelination created in the internal capsule (ic) area of the rat brain using lysophosphatidyl choline (LPC). "
05/01/2004 - "During acute demyelination by lysophosphatidyl-choline, the surface area of compound action potential decreased probably because conduction block occurred. "
06/01/2002 - "The increase in the intensity of the choline resonance during the early phase is indicative of the onset of an inflammatory demyelination process, and its rapid decrease thereafter is due to reduction in the inflammatory process associated with remyelination. "

05/01/1999 - "Glial cell transplantation has the potential to be developed into a clinical treatment for human demyelinating diseases because of its demonstrated efficacy in remyelinating experimentally demyelinated axons. "
09/01/2014 - "The first transplantation studies in animal models for demyelination with iPSC-derived OPCs demonstrated their survival and remyelinating capacity, but also revealed their limited migration capacity. "
05/01/2014 - "Cell integration as well as demyelination extension and myelination intensity changes were evaluated using histologic studies and immunocytochemistry after 2 and 4 weeks post transplantation. "
07/01/2011 - "At present, transplantation of myelinating cells is regarded as a promising strategy for treating demyelination following SCI. Hence, the In vitro culture and growth, differentiation and proliferation of oligodendrocyte precursor cells (OPCs) were intensively investigated in this study. "
06/01/2007 - "This study indicates that the environment of demyelination in 30-day-old twitcher mouse brain has not significantly altered the engraftment and distribution patterns of NSCs after neonatal transplantation."

06/01/2004 - "This study demonstrates for the first time that transplant-mediated remyelination is possible in the pathogenic environment of the MHV demyelination model and that it is associated with locomotor improvement."
12/01/1988 - "However, pathologic studies performed 8.5 months after the initial transplant revealed residual central nervous system demyelination."
01/01/2013 - "Mesenchymal stromal-cell transplants induce oligodendrocyte progenitor migration and remyelination in a chronic demyelination model."
11/01/2012 - "Immune mediated demyelinating disease (IMDD) after allogeneic hemopoietic stem cell transplant (HSCT) is rare and its etiology unclear. "
02/15/2008 - "Based on this analysis the case is made that only areas of acute demyelination will be amenable to transplant-mediated remyelination. "

06/01/1993 - "Results of this uncontrolled study suggest that plasmapheresis in the absence of other immunosuppressive drugs may have a role in the treatment of severe episodes of inflammatory demyelination in a select subset of MS patients."
06/01/2001 - "Plasmapheresis may be a successful treatment for the type of inflammatory demyelination shown in the present case."
06/01/1993 - "Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination."
11/01/1990 - "Increased proliferation of blood mononuclear cells after plasmapheresis treatment of patients with demyelinating disease."
08/01/1986 - "Considerable controversy exists with regard to therapeutic efficacy of plasmapheresis in the immune-mediated demyelinating disorders of the peripheral and central nervous system: acute inflammatory polyneuropathy (Guillain-Barré syndrome), chronic inflammatory demyelinating polyneuropathy, and multiple sclerosis. "

04/01/2009 - "Plasma exchange (PE) is increasingly undertaken in diseases involving humoral factors and is proven to be beneficial in acute demyelinating diseases. "
06/01/2015 - "This retrospective study suggests that plasma exchange can be effective in ameliorating symptoms in severe pediatric central nervous system inflammatory demyelination, although lack of randomization or control group limits the ability to attribute this outcome entirely to plasma exchange. "
01/01/2001 - "However, several uncontrolled studies have suggested that patients with severe attacks of MS and other inflammatory demyelinating disease may improve rapidly after plasma exchange treatment. "
12/01/1999 - "A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease."
06/01/2015 - "We describe 12 children treated with plasma exchange for acute severe central nervous system inflammatory demyelination. "

09/01/2010 - "Further studies are required to assess the safety and efficacy of second-line treatments in children with MS. The present article constitutes an update of the existing publications regarding treatment of acute events of CNS demyelination in children and adolescents as well as considerations for the use of immunomodulatory therapies."
01/01/2007 - "An unsuccessful trial of immunomodulatory therapy in delayed posthypoxic demyelination."
06/01/2008 - "Based on the complexity of the demyelination and remyelination processes, it should be expected that effective therapeutic approaches will require a combination of strategies for immunomodulation, neuroprotection, and myelin replacement. "
09/01/2015 - "However, recurrent demyelinating disorders like multiple sclerosis and NMO required long-term immunomodulation. "
02/01/2010 - "There is good evidence for the efficacy and tolerability of immunomodulatory therapies in GBS, myasthenia gravis, and acute central nervous system demyelination, though data to establish superiority of one therapeutic regimen over another remains lacking. "